Diagnostic value of interleukin-8 in colon cancer: Prospective, case-control study

Table 3 Subgroup analysis of serum interleukin-8 levels according to clinicopathological features

Variable	Category	Number	IL-8 (pg/mL)	P value1
Tumor location, median (IQR)	Right colon	10	53.20 (37.38-66.63)
	Left colon	31	44.61 (35.59-60.83)
	Synchronous	3	77.65 (41.10-91.40)	0.2223
T stage, median (IQR)	T2	3	44.61 (43.62-60.79)
	T3	27	52.66 (35.91-60.06)
	T4	14	56.56 (30.80-66.45)	0.9124
N stage, median (IQR)	N0	24	45.61 (35.66-68.13)
	N1	15	53.29 (35.91-63.14)
	N2	5	56.85 (34.76-59.72)	0.9988
Overall stage, median (IQR)	Stage 1	4	46.60 (38.68-79.07)
	Stage 2	21	53.10 (33.62-62.79)
	Stage 3	13	46.60 (36.72-76.97)
	Stage 4	6	53.10 (34.12-62.45)	0.9585
Lymphovascular invasion, median (IQR)	Absent	13	46.60 (38.68-79.07)
	Present	31	53.10 (33.62-62.79)	0.6433
Perineural invasion, median (IQR)	Absent	21	46.60 (36.72-76.97)
	Present	23	53.10 (34.12-62.45)	0.7870
Microsatellite instability, median (IQR)	MSS/MSI-L	40	53.20 (35.50-66.12)
	MSI-H	4	44.28 (39.48-47.58)	0.3373
Mode of presentation, median (IQR)	Elective	29	53.10 (36.72-65.87)
	Emergency	14	50.38 (31.69-63.10)	0.5685

¹P values were calculated using Kruskal-Wallis test for variables with more than two categories and Mann-Whitney U test for binary variables.

IQR: Interquartile range; IL-8: Interleukin-8; MSS: Microsatellite stable; MSI-L: Microsatellite instability-low; MSI-H: Microsatellite instability-high.